Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.19 on Friday. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.68. The business has a fifty day simple moving average of $0.31 and a 200 day simple moving average of $0.49. The company has a market cap of $11.29 million, a P/E ratio of -0.06 and a beta of 1.06.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.